Dabrafenib (GSK2118436)

Catalog No.S2807

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Cited by 104 Publications

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Discov, 2018, 8(4):417-427

PubMed: 29431697 ( click the link to review the publication )

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Nat Med, 2016, 22(9):1056-61

PubMed: 27500726 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Mol Cell, 2019, 76(6):872-884

PubMed: 31606273 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0298-5

PubMed: 30742091 ( click the link to review the publication )

Eur J Cancer, 2019, 109:137-153

PubMed: 30721788 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):272

PubMed: 31227006 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):56

PubMed: 30728057 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31533235 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12824

PubMed: 31518489 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )
Acta Neuropathol Commun, 2019, 7(1):128

PubMed: 31391125 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):119

PubMed: 31345255 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113616

PubMed: 31445021 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1225

PubMed: 30718660 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:223

PubMed: 31467489 ( click the link to review the publication )

Surgery, 2019, 10.1016/j.surg.2019.04.076

PubMed: 31585718 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Metabolites, 2019, 9(11)

PubMed: 31744229 ( click the link to review the publication )

Chembiochem, 2019, 10.1002/cbic.201900266

PubMed: 31152574 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0217399

PubMed: 31158244 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

Reprod Domest Anim, 2019, 54(5):741-749

PubMed: 30785650 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Mol Cell, 2018, 69(6):923-937

PubMed: 29547721 ( click the link to review the publication )

Mol Cell, 2018, 70(5):920-935

PubMed: 29883609 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2500

PubMed: 29950559 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1466

PubMed: 29654229 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )
Clin Cancer Res, 2018, 24(14):3377-3385

PubMed: 29650750 ( click the link to review the publication )

Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):84-95

PubMed: 29133617 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Oncol, 2018, 12(1):74-88

PubMed: 29112787 ( click the link to review the publication )

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(22):3974-3985

PubMed: 30137437 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9991

PubMed: 29968772 ( click the link to review the publication )

Front Pharmacol, 2018, 9:856

PubMed: 30154717 ( click the link to review the publication )

ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36503-36514

PubMed: 30559933 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28294-28308

PubMed: 29983861 ( click the link to review the publication )

Neural Regen Res, 2018, 13(2):252-256

PubMed: 29557374 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4684-4696

PubMed: 28652244 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(19):3631-3645

PubMed: 28551825 ( click the link to review the publication )
Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15523

PubMed: 29138474 ( click the link to review the publication )

Anal Bioanal Chem, 2017, 409(15):3749-3756

PubMed: 28429064 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2741-2751

PubMed: 29048639 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68208-68220

PubMed: 28978109 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(11 Pt B):2980-2992

PubMed: 28408301 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(10):1776-1790

PubMed: 27464255 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

J Biol Chem, 2016, 291(34):17804-15

PubMed: 27226552 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )

Oncotarget, 2016, 8(35):58021-58036

PubMed: 28938534 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30453-60

PubMed: 27028853 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(8):2021-2030

PubMed: 25748555 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Eur J Pharmacol, 2015, 762:283-92

PubMed: 26048310 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )
PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Targets

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-Raf^V600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-Raf^V600E. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	MkDLT4lv[XOnIFHzd4F6				MnrTTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd{B1[WepZXSgRk1T[WZiVk[wNGUhdXW2YX70JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiY3XscJMh[29vZYjwdoV{e2mwZzDDSGM{PyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBjcW:2aX75cIF1\WRvTVXLJJBzd3SnaX6gdIhwe3Cqb4L5cIF1cW:wIHL5JGFteGijU3Py[YVvKGG\|c3H5JJdqfGhiSVO1NEBw\iByLkCwNFch\|ryP	M{fNNVI1QTByNkez
SK-MEL-28	MoT5T4lv[XOnIFHzd4F6		MlLxNUBp		MXHJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCVSz3NSWwuOjhiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gSXJMKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFQh\|ryP	NF3KcnUzPDlyME[3Ny=>
HepG2	NFi1d5lMcW6jc3WgRZN{[Xl?				MnLvTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRiaX6gbJVu[W5iSHXwS\|Ih[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iRWLLJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMESg{txO	NVfjcI01OjR7MEC2O\|M>
COLO205	NHjER3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGX6[pZKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:yNFUh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjCwMlAxPyEQvF2=	MnLYNlQ6ODB4N{O=
HepG2	MnvESpVv[3Srb36gRZN{[Xl?		MWG0OUBucW5?	M1\1VGROW09?	NUP4[oc4UW6qaXLpeIlwdiCxZjDBcIs2KGmwIGTHSk1j\XSjLYP0bY12dGG2ZXSgbJVu[W5iSHXwS\|Ih[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iU33h[FIheGixc4Doc5J6dGG2aX;uJJRz\WG2ZXSg[o9zKDR3IH3pcpMheHKrb4KgeI8hXEeILXLleIEhe3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhPjBibXnud{BjgSCxZInzd4V6KGKub4Sgd4Nidm6ncjDhcoFtgXOrczD3bZRpKEmFNUCgc4YhOy55IN88US=>	NWLXTY45OjR7MEC2O\|M>
HFF	M4W1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPvNVAh\|ryP	M4W4XFczKGh?	NUXsbGQ1TE2VTx?=	NVXBRWdRUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIHj1cYFvKEiIRjDj[YxteyCqYYLic5Jqdmdid3ns[EB1gXCnIFKtVoFnKHerdHigTWM2OCCxZjCzJO69VQ>?	M3nqXFI{QDR2MEO4
SK-MEL-28	NYrwdZJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTxNVAyOCEQvF2=	NInzXIc4OiCq	NHTQdnNFVVOR	Mkn3TY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvZILpeoVvKFONLV3FUE0zQCClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODR\|IN88US=>	NIPL[ZAzOzh2NECzPC=>
A375P-F11	M{ewVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDoe\|ZOOTBizszN	NHPYZm84OiCq	MVrEUXNQ	M1nQUWlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCDM{e1VE1HOTFiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB5MTFOwG0>	MUmyN\|g1PDB\|OB?=
MALME-3M	NFjDbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzXNVAh\|ryP	NF\PT5A4OiCq	MnTMSG1UVw>?	NWrj[VIzUUN3ME2xJI5O	M3TpdFI{QDR2MEO4
UACC-62	MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYmxNEDPxE1?	NUTYcphNPzJiaB?=	MonTSG1UVw>?	MknHTWM2OD1zIH7N	MXuyN\|g1PDB\|OB?=
C32TG	NELYVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2Pxd\|ExKM7:TR?=	MWK3NkBp	M4LC[2ROW09?	MYjJR\|UxRTFibl2=	MWCyN\|g1PDB\|OB?=
SK-MEL-1	M3qwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnONW0yOCEQvF2=	NXLmU4R6PzJiaB?=	MX;EUXNQ	NFL0fXZKSzVyPUKgcm0>	Mn3qNlM5PDRyM{i=
M14	NWH1T\|M3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DkPFExKM7:TR?=	NEn4Noo4OiCq	NYe5cJdUTE2VTx?=	MVXJR\|UxRTJibl2=	M{nifVI{QDR2MEO4
SK-MEL-28	M{PKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEH1UocyOCEQvF2=	M{KzSlczKGh?	NGLjW\|lFVVOR	NHq1Z5FKSzVyPUOgcm0>	MoXpNlM5PDRyM{i=
A375	NIHvS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWm1bYhmOTBizszN	M33rO\|czKGh?	NUS0fIVyTE2VTx?=	M4jVXmlEPTB;NDDuUS=>	M3faZVI{QDR2MEO4
DU-4475	M2m2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEixWo4yOCEQvF2=	MmT5O\|IhcA>?	M4iwcGROW09?	NHL3doZKSzVyPUWgcm0>	NGPJXoczOzh2NECzPC=>
UACC-257	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\vPFExKM7:TR?=	NG\VVXA4OiCq	M1i0d2ROW09?	MkXFTWM2OD14IH7N	NF\MSXIzOzh2NECzPC=>
Colo 205	M3;nVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfEOYYyOCEQvF2=	M4DvdFczKGh?	MWrEUXNQ	NVP1ZVBiUUN3ME23JI5O	NVn0bGViOjN6NESwN\|g>
SK-MEL-3	NXjzV\|NoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHr3flMyOCEQvF2=	MUO3NkBp	MnPLSG1UVw>?	M3zOfmlEPTB;NzDuUS=>	NFTZTWgzOzh2NECzPC=>
SH-4	M2W1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHxeY4yOCEQvF2=	NV;yT3FUPzJiaB?=	MnTqSG1UVw>?	NETubYhKSzVyPUigcm0>	MVSyN\|g1PDB\|OB?=
A101D	M3nkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHNT\|EyOCEQvF2=	NGDZcpc4OiCq	NF;R[m9FVVOR	M1jye2lEPTB;OTDuUS=>	MWeyN\|g1PDB\|OB?=
ES-2	NEHlTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYexNEDPxE1?	MoHuO\|IhcA>?	MlvKSG1UVw>?	M{nDVmlEPTB;NUOgcm0>	MXKyN\|g1PDB\|OB?=
HT-29	NVXVRpdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfrRnUyOCEQvF2=	M135UlczKGh?	M3v2PWROW09?	MY\JR\|UxRTZ4IH7N	M1PK[VI{QDR2MEO4
SW1417	Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVOxNEDPxE1?	MknlO\|IhcA>?	MYPEUXNQ	NY\YfG82UUN3ME2xOVghdk1?	NI\xUYkzOzh2NECzPC=>
SW872	NWrVTYpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnBNVAh\|ryP	MVO3NkBp	NFHLeW9FVVOR	NIXob5NKSzVyPUO3O{BvVQ>?	NFTvbJMzOzh2NECzPC=>
RKO	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjUNVAh\|ryP	M4nmR\|czKGh?	M{XTZmROW09?	MYPJR\|UxRTJwNUKyJO69VQ>?	MYiyN\|g1PDB\|OB?=
A673	NHvzeXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjwcZNQOTBizszN	M2K3dFczKGh?	MYXEUXNQ	NUD2dJRtUUN3ME2xNEDPxE1?	Mkf1NlM5PDRyM{i=
GCT	NFXl[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TYU\|ExKM7:TR?=	MUG3NkBp	M3P6fWROW09?	MYPJR\|UxRTFyIN88US=>	M{W3WFI{QDR2MEO4
WM-115	NYTITXZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVyxNEDPxE1?	MnvyO\|IhcA>?	M4PwfWROW09?	M4XZNGlEPTB;NTDuUS=>	M3Tkd\|I{QDR2MEO4
YUMAC	NV3oV\|dQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fLNVExKM7:TR?=	M{LGSlczKGh?	NHPKfXBFVVOR	MkLvTWM2OD13IH7N	NU[0W2VjOjN6NESwN\|g>
OV-90	NILCWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jS[lExKM7:TR?=	MVy3NkBp	NVHkepg3TE2VTx?=	MUfJR\|UxRTJ7IH7N	MnSxNlM5PDRyM{i=
NCI-H508	NY\RSpM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PGU\|ExKM7:TR?=	MW[3NkBp	MlL4SG1UVw>?	MmXPTWM2OD1zMDFOwG0>	M2rZPFI{QDR2MEO4
MDA-MB-231	NYX2b2piT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXWxNEDPxE1?	MUC3NkBp	NF7ne5hFVVOR	NGfTZYFKSzVyPUGwJO69VQ>?	NVfRRXpSOjN6NESwN\|g>
SW756	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX75cJc3OTBizszN	NVPLcoZyPzJiaB?=	NGLJO2xFVVOR	NHPMd4tKSzVyPUGwJO69VQ>?	NULmR5E1OjN6NESwN\|g>
SW-837	M4C4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\qXVExKM7:TR?=	MYG3NkBp	MmXVSG1UVw>?	M3rVfWlEPTB;MUCg{txO	Mk\FNlM5PDRyM{i=
UMUC-3	M1X5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfsTHlDOTBizszN	NXPG[W9wPzJiaB?=	NWnrfoxZTE2VTx?=	MWLJR\|UxRTFyIN88US=>	MY[yN\|g1PDB\|OB?=
LS-174T	NF3IcXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEf0UmIyOCEQvF2=	MUO3NkBp	NHv5RWNFVVOR	M{HRPGlEPTB;MUCg{txO	Ml\QNlM5PDRyM{i=
A549	MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXoNVAh\|ryP	Mn3IO\|IhcA>?	MVzEUXNQ	NGW1cJVKSzVyPUGwJO69VQ>?	NVjh[\|RZOjN6NESwN\|g>
SHP-77	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLINVAh\|ryP	MkfCO\|IhcA>?	MWTEUXNQ	NVnzNm1nUUN3ME2xNEDPxE1?	NHjZOngzOzh2NECzPC=>
SW480	NFiwWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jYelExKM7:TR?=	NH;lTGw4OiCq	NUPORXppTE2VTx?=	M1\MS2lEPTB;MUCg{txO	NXXNSlBSOjN6NESwN\|g>
DLD-1	M{LRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV[xNEDPxE1?	MmPiO\|IhcA>?	NWXTSI1zTE2VTx?=	NXnEc3RiUUN3ME2xNEDPxE1?	MYmyN\|g1PDB\|OB?=
HCT-116	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfpPI9zOTBizszN	M2foT\|czKGh?	NIjXVYpFVVOR	NEfUd\|dKSzVyPUGwJO69VQ>?	Mom1NlM5PDRyM{i=
NCI-H747	NGLqWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUmzdJR2OTBizszN	NXvRdXRoPzJiaB?=	NXnqTJBwTE2VTx?=	MnTaTWM2OD1zMDFOwG0>	MoW3NlM5PDRyM{i=
T-84	M4rtT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTjNVAh\|ryP	NWPVXXBVPzJiaB?=	MVXEUXNQ	MYjJR\|UxRTFyIN88US=>	NXTmWnBoOjN6NESwN\|g>
NCI-H460	M4T6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1mySFExKM7:TR?=	MnjoO\|IhcA>?	NGniTmRFVVOR	NXXNNI5HUUN3ME2xNEDPxE1?	MmW5NlM5PDRyM{i=
Calu-6	MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHSb5AyOCEQvF2=	NVrpd4JnPzJiaB?=	NEntb41FVVOR	NWfXZ3RqUUN3ME2xNEDPxE1?	MoTFNlM5PDRyM{i=
HCC-2998	NYqzPVFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2Du[\|ExKM7:TR?=	NEnJOpo4OiCq	NF3qeZpFVVOR	NV3ZWZUyUUN3ME2xNEDPxE1?	MYKyN\|g1PDB\|OB?=
LS1034	NXT4ZXVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zFOVExKM7:TR?=	NF3iT4g4OiCq	NF7UT5JFVVOR	NED2UXJKSzVyPUGwJO69VQ>?	MXiyN\|g1PDB\|OB?=
CHP-212	M4PxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PKeFExKM7:TR?=	NYHkfG5mPzJiaB?=	M2nlUmROW09?	MV\JR\|UxRTFyIN88US=>	NVvwenp2OjN6NESwN\|g>
SK-N-AS	M{CyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXuxNEDPxE1?	MoTFO\|IhcA>?	NEK2[lZFVVOR	MlPPTWM2OD1zMDFOwG0>	MoTwNlM5PDRyM{i=
BFTC-905	MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnf6NVAh\|ryP	NUOwdFJQPzJiaB?=	MVPEUXNQ	MWDJR\|UxRTFyIN88US=>	NV7EOGtmOjN6NESwN\|g>
HuT78	NWX6cmdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVqxNEDPxE1?	MmHBO\|IhcA>?	M2TETWROW09?	M4nZT2lEPTB;NUKgcm0>	NXfTRllKOjN6NESwN\|g>
RPMI-8226	M{DuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LHXFExKM7:TR?=	MmfmO\|IhcA>?	NWHVZ5p6TE2VTx?=	Ml3hTWM2OD1{NkOgcm0>	M{LTUlI{QDR2MEO4
BC-3	NUfsWXBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnaeYdxOTBizszN	MofuO\|IhcA>?	MmPGSG1UVw>?	MXPJR\|UxRTJ5NzDuUS=>	MXqyN\|g1PDB\|OB?=
ACHN	Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nRfVExKM7:TR?=	NFXucGo4OiCq	MXTEUXNQ	M2jKUGlEPTB;Mkm0JI5O	Mmn2NlM5PDRyM{i=
JRT3-T35	M1PySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2H4dlExKM7:TR?=	NG[2doE4OiCq	MXrEUXNQ	MnH2TWM2OD1{OUWgcm0>	MlPiNlM5PDRyM{i=
SK-MES-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHL5WVQyOCEQvF2=	NW[wbGZ6PzJiaB?=	MniySG1UVw>?	MX3JR\|UxRTN{OTDuUS=>	MU[yN\|g1PDB\|OB?=
CESS	NVXESXVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUmxNEDPxE1?	NUfzUoJbPzJiaB?=	NWrPbpYzTE2VTx?=	MVPJR\|UxRTR7NzDuUS=>	NX\QWId2OjN6NESwN\|g>
H4	M4jHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3CNVAh\|ryP	NW\6R2lsPzJiaB?=	Mln1SG1UVw>?	M4rFVGlEPTB;NkG5JI5O	M3O0VlI{QDR2MEO4
BC-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHPNVAh\|ryP	MmexO\|IhcA>?	Mnn2SG1UVw>?	MoKwTWM2OD15MESgcm0>	NW[0UI86OjN6NESwN\|g>
DB	NVLPcm9FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmS1NVAh\|ryP	MlHOO\|IhcA>?	NGPLdGRFVVOR	M2P3XWlEPTB;OEezJI5O	NXmwSHpyOjN6NESwN\|g>
RPMI-6666	MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPvXHZUOTBizszN	NHzFdpE4OiCq	NXGy[WVqTE2VTx?=	NVTaNlVLUUN3ME25Nlghdk1?	MYSyN\|g1PDB\|OB?=
MC/CAR	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LqUFExKM7:TR?=	MlnTO\|IhcA>?	Ml\QSG1UVw>?	NYjr[nprUUN3ME2xMlAxOiEQvF2=	MlrWNlM5PDRyM{i=
SNU-1	M2fIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\iS\|ExKM7:TR?=	M2TNe\|czKGh?	NYnFUVJHTE2VTx?=	NE\FOGtKSzVyPUGuOVAyKM7:TR?=	MViyN\|g1PDB\|OB?=
CEM/C1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfiUJQyOCEQvF2=	M{[wVVczKGh?	MlPYSG1UVw>?	NIHoO4pKSzVyPUGuO\|c{KM7:TR?=	NGj0PVMzOzh2NECzPC=>
GDM-1	MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnhd21VOTBizszN	NFLiZmQ4OiCq	NYCxRm41TE2VTx?=	M1TKbGlEPTB;MT65PVch\|ryP	MUCyN\|g1PDB\|OB?=
HT-1080	M4\0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vob\|ExKM7:TR?=	NFPC[\|M4OiCq	MoHNSG1UVw>?	NXXodJNuUUN3ME2yMlAxPCEQvF2=	M{jZWFI{QDR2MEO4
HL-60	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnqbppiOTBizszN	NWf2SnlCPzJiaB?=	MoLESG1UVw>?	Mni4TWM2OD1{LkG3PEDPxE1?	MYiyN\|g1PDB\|OB?=
C3A	M37CSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfmNFEyOCEQvF2=	NEKwVGM4OiCq	NILFPGJFVVOR	Mne5TWM2OD13LkSxOEDPxE1?	NUXkemhjOjN6NESwN\|g>
MES-SA	MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljvNVAh\|ryP	NX\LN5BJPzJiaB?=	MYjEUXNQ	MV;JR\|UxRTZwOUi5JO69VQ>?	MoLJNlM5PDRyM{i=
22Rv1	MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUOxNEDPxE1?	MXK3NkBp	M1nUcmROW09?	NVfadJljUUN3ME2xNEDPxE1?	MXKyN\|g1PDB\|OB?=
647-V	MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4Ll[FExKM7:TR?=	NVvXVm5IPzJiaB?=	M3rU[2ROW09?	NInsNo9KSzVyPUGwJO69VQ>?	MWOyN\|g1PDB\|OB?=
786-O	NX31UZMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnQcldyOTBizszN	M{fvRVczKGh?	NHTlZ\|dFVVOR	NXvDXmtIUUN3ME2xNEDPxE1?	NUjkTYFsOjN6NESwN\|g>
A172	NVf3NlVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVGxNEDPxE1?	M4jxT\|czKGh?	M3nKV2ROW09?	NHSxWW5KSzVyPUGwJO69VQ>?	Ml3PNlM5PDRyM{i=
A204	NIrYeZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVn1SHFPOTBizszN	M1jqblczKGh?	NFTr[49FVVOR	M1jCcGlEPTB;MUCg{txO	NVX3VVd{OjN6NESwN\|g>
A427	M4PvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPxeVQyOCEQvF2=	NHXEflk4OiCq	NXq0OHl1TE2VTx?=	NEXIPW5KSzVyPUGwJO69VQ>?	MkS1NlM5PDRyM{i=
A431	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVmxNEDPxE1?	NHX3UYc4OiCq	M1rL[WROW09?	MVfJR\|UxRTFyIN88US=>	NGXtV44zOzh2NECzPC=>
A2780	NFuwUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2H6SVExKM7:TR?=	NGS0UXk4OiCq	M4\LTWROW09?	MWjJR\|UxRTFyIN88US=>	NUfUN24{OjN6NESwN\|g>
ARH-77	NX[2NJlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV[ybHM1OTBizszN	M1\TUlczKGh?	MXzEUXNQ	M3TOU2lEPTB;MUCg{txO	NXfQNYx7OjN6NESwN\|g>
Be(2)C	NVv1RndUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLQflZjOTBizszN	M2jnfVczKGh?	Mn74SG1UVw>?	NYHCd4pTUUN3ME2xNEDPxE1?	MkXzNlM5PDRyM{i=
BT-20	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrHSngyOCEQvF2=	M3;iNFczKGh?	MY\EUXNQ	MXfJR\|UxRTFyIN88US=>	NEGwZnkzOzh2NECzPC=>
BxPc3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLDNVAh\|ryP	NG[1WHU4OiCq	MlTVSG1UVw>?	M2GxNmlEPTB;MUCg{txO	NYrCbWREOjN6NESwN\|g>
C-4 I	MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYSxNEDPxE1?	NWPsU2lsPzJiaB?=	NGfvWFhFVVOR	NGLIfYdKSzVyPUGwJO69VQ>?	NH3OZlIzOzh2NECzPC=>
C33A	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;NboIyOCEQvF2=	MXu3NkBp	NXHEfmg1TE2VTx?=	NILJTYFKSzVyPUGwJO69VQ>?	M1TkRlI{QDR2MEO4
CAL-27	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrhNVAh\|ryP	M3PSOFczKGh?	MUfEUXNQ	NELQe2pKSzVyPUGwJO69VQ>?	MUGyN\|g1PDB\|OB?=
CAL-62	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYGxNEDPxE1?	MXi3NkBp	NH;qZm9FVVOR	MnzUTWM2OD1zMDFOwG0>	NGnUeJEzOzh2NECzPC=>
Calu-3	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;aNVAh\|ryP	MX[3NkBp	MWXEUXNQ	M3HpfmlEPTB;MUCg{txO	Ml\oNlM5PDRyM{i=
CaOV3	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjqNVAh\|ryP	NHjOfHE4OiCq	NW\WeHZuTE2VTx?=	NYTsfmlFUUN3ME2xNEDPxE1?	NGiyOmczOzh2NECzPC=>
CGTHW1	NFXqPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVP6NWdQOTBizszN	M{DmRVczKGh?	NVO4elBCTE2VTx?=	NHPBenhKSzVyPUGwJO69VQ>?	NEDHU2kzOzh2NECzPC=>
CHL-1	NUOwZYdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGflNIcyOCEQvF2=	NF;0eWc4OiCq	NG\kfpFFVVOR	NVvtR4xDUUN3ME2xNEDPxE1?	MlnFNlM5PDRyM{i=
Colo320DM	M{HaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV6xNEDPxE1?	NUniN5hpPzJiaB?=	NGHaUXZFVVOR	NVroO3VUUUN3ME2xNEDPxE1?	NEXhNXkzOzh2NECzPC=>
Colo704	Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYOxNEDPxE1?	MmfPO\|IhcA>?	NWW2SYxQTE2VTx?=	Mnq5TWM2OD1zMDFOwG0>	MmK4NlM5PDRyM{i=
COR-L23	Mn3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7EeI1lOTBizszN	MluxO\|IhcA>?	NYXUeoF4TE2VTx?=	MVvJR\|UxRTFyIN88US=>	MnzNNlM5PDRyM{i=
CRO-AP2	NHva[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXf6[YJxOTBizszN	MWe3NkBp	MkjGSG1UVw>?	MYPJR\|UxRTFyIN88US=>	NIOzfGgzOzh2NECzPC=>
Daudi	M{DzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHOXWJrOTBizszN	NEK2[YE4OiCq	NYm4b4l7TE2VTx?=	MVnJR\|UxRTFyIN88US=>	NF3NTI0zOzh2NECzPC=>
DOTC 24510	NUD3XXVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTxS5pVOTBizszN	NHzQd\|k4OiCq	NIHlPHlFVVOR	M{X3SmlEPTB;MUCg{txO	MkK3NlM5PDRyM{i=
DU-145	MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnv4NVAh\|ryP	NXzCWGNsPzJiaB?=	MYDEUXNQ	Mof4TWM2OD1zMDFOwG0>	NEfTfXczOzh2NECzPC=>
EB-3	M4nzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUKxNEDPxE1?	MnvwO\|IhcA>?	NX3mUVFTTE2VTx?=	NWXVO3V{UUN3ME2xNEDPxE1?	NGHVWlIzOzh2NECzPC=>
EFM-19	NWr1fFR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPKZWkyOCEQvF2=	MkDiO\|IhcA>?	MYjEUXNQ	MoXQTWM2OD1zMDFOwG0>	NFfsNYQzOzh2NECzPC=>
EKVX	M1XTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3ZcWo2OTBizszN	NGW0dIY4OiCq	NFX6UWhFVVOR	MWLJR\|UxRTFyIN88US=>	M3XJ[VI{QDR2MEO4
FaDu	Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY[xNEDPxE1?	MWK3NkBp	MmDkSG1UVw>?	MXvJR\|UxRTFyIN88US=>	NVfxT4pTOjN6NESwN\|g>
G401	NXvRUXdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mom2NVAh\|ryP	MWm3NkBp	MXHEUXNQ	NFP2[IdKSzVyPUGwJO69VQ>?	MUiyN\|g1PDB\|OB?=
HCC-70	M3XEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoP3NVAh\|ryP	NUPabFVyPzJiaB?=	MXjEUXNQ	MW\JR\|UxRTFyIN88US=>	M123O\|I{QDR2MEO4
HCC-1954	NUTrZY1jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3O4PVExKM7:TR?=	NH\vTpc4OiCq	MnrwSG1UVw>?	Mn;zTWM2OD1zMDFOwG0>	NGDNS3YzOzh2NECzPC=>
Hela	NFO5SYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnx[VIyOCEQvF2=	NHHxS4k4OiCq	MV;EUXNQ	NE\SNYZKSzVyPUGwJO69VQ>?	MX2yN\|g1PDB\|OB?=
Hep3B	M2r0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrBUlgyOCEQvF2=	NXfYT3JzPzJiaB?=	NGi1dmNFVVOR	NIDrVoZKSzVyPUGwJO69VQ>?	NW\RZW1VOjN6NESwN\|g>
HMCB	NXfJW4g2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUSxNEDPxE1?	MnvBO\|IhcA>?	NETacGRFVVOR	MnL2TWM2OD1zMDFOwG0>	M4[zUlI{QDR2MEO4
HN5	NX3aWmM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYKxNEDPxE1?	NIX5XHQ4OiCq	MnzISG1UVw>?	M4j2O2lEPTB;MUCg{txO	M4nST\|I{QDR2MEO4
HOS	MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXTVW1VOTBizszN	M4DvSFczKGh?	Mom1SG1UVw>?	M1\FWmlEPTB;MUCg{txO	NVy1[4M2OjN6NESwN\|g>
HPAF-II	NYiyS5hKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3m3UlExKM7:TR?=	MVm3NkBp	MmHJSG1UVw>?	M4nkeGlEPTB;MUCg{txO	NInRT48zOzh2NECzPC=>
Hs746.T	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvQN\|MyOCEQvF2=	NHjYOpg4OiCq	NHrBOVlFVVOR	NUPJRmJHUUN3ME2xNEDPxE1?	NFTqT48zOzh2NECzPC=>
HT	NXXkV3pjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3xTIVCOTBizszN	M1\XclczKGh?	M1X2d2ROW09?	NYPSPFl6UUN3ME2xNEDPxE1?	M1TXUFI{QDR2MEO4
HT-3	MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXSRXgyOCEQvF2=	M{DyWFczKGh?	MmjrSG1UVw>?	NVrLNXJ{UUN3ME2xNEDPxE1?	MkLTNlM5PDRyM{i=
HuNS-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXyxNEDPxE1?	M{ewW\|czKGh?	M1HTTGROW09?	MYXJR\|UxRTFyIN88US=>	NXPuW\|g6OjN6NESwN\|g>
IGROV1	NF\HTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDiS\|UyOCEQvF2=	M2P2Z\|czKGh?	NYTIVG9rTE2VTx?=	MUnJR\|UxRTFyIN88US=>	MWGyN\|g1PDB\|OB?=
J82	NVvySFR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV:xNEDPxE1?	NFvtWG84OiCq	M1;FXWROW09?	MUfJR\|UxRTFyIN88US=>	MmPsNlM5PDRyM{i=
JM1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NED6dpoyOCEQvF2=	NVLtbGdvPzJiaB?=	M1WwN2ROW09?	M17sSGlEPTB;MUCg{txO	M{DOOFI{QDR2MEO4
Kato III	M4XjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLQS2cyOCEQvF2=	M1fIe\|czKGh?	NHXlbYhFVVOR	MX7JR\|UxRTFyIN88US=>	MVOyN\|g1PDB\|OB?=
KHOS-240S	MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3ZUIkyOCEQvF2=	MoHhO\|IhcA>?	MoT3SG1UVw>?	Mn7JTWM2OD1zMDFOwG0>	MnfnNlM5PDRyM{i=
KM-12	M{jqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFH3PWcyOCEQvF2=	NX;YeGM2PzJiaB?=	NY\LV44zTE2VTx?=	M{\IVmlEPTB;MUCg{txO	NXXYSJVzOjN6NESwN\|g>
KPL-1	M3fvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfUUFI6OTBizszN	NIqzWHE4OiCq	NHTzNpdFVVOR	Mm\QTWM2OD1zMDFOwG0>	MXiyN\|g1PDB\|OB?=
KYSE-30	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjiUFJQOTBizszN	Mn74O\|IhcA>?	NWPZe2dnTE2VTx?=	NHjtblRKSzVyPUGwJO69VQ>?	NGHhU44zOzh2NECzPC=>
LNCaP	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPWNHYyOCEQvF2=	MWO3NkBp	MUTEUXNQ	M{PJVGlEPTB;MUCg{txO	NGLPPXczOzh2NECzPC=>
MCF-7	MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHLNYMyOCEQvF2=	NXHBV5A{PzJiaB?=	M1LIdGROW09?	NXjZUXBHUUN3ME2xNEDPxE1?	NY\hdGlqOjN6NESwN\|g>
MC-IXC	MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWOxNEDPxE1?	M2rYO\|czKGh?	M1jrSmROW09?	MWTJR\|UxRTFyIN88US=>	NV20PINROjN6NESwN\|g>
MDA-MB-175 VII	Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfIU20yOCEQvF2=	NW\QeopTPzJiaB?=	M1\Gc2ROW09?	NY\I[HpyUUN3ME2xNEDPxE1?	NWP2S2ZIOjN6NESwN\|g>
MDA-MB-468	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUCxNEDPxE1?	MnrEO\|IhcA>?	NWXFcJA2TE2VTx?=	Mn\4TWM2OD1zMDFOwG0>	NVPyTWFTOjN6NESwN\|g>
MiaPaCa	NXjYO21qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnTWWdkOTBizszN	NUfoTIU6PzJiaB?=	MkTPSG1UVw>?	NHrOWGRKSzVyPUGwJO69VQ>?	MW[yN\|g1PDB\|OB?=
Molt-4	NHzOUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTSSFVIOTBizszN	MlzpO\|IhcA>?	NGPBOHVFVVOR	MX\JR\|UxRTFyIN88US=>	M3;vflI{QDR2MEO4
NCI-ADR/RES	M2LRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVOxNEDPxE1?	MmDtO\|IhcA>?	MUPEUXNQ	NUnS[mk4UUN3ME2xNEDPxE1?	NFOzNlMzOzh2NECzPC=>
NCI-H69	NETsfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV2xNEDPxE1?	MormO\|IhcA>?	Ml7USG1UVw>?	Ml\2TWM2OD1zMDFOwG0>	NH34ZlgzOzh2NECzPC=>
NCI-H82	NUPaVIVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkL4NVAh\|ryP	MXK3NkBp	MUTEUXNQ	NWq4PZNoUUN3ME2xNEDPxE1?	M3izb\|I{QDR2MEO4
NCI-N87	M{GxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PFVFExKM7:TR?=	NUHCWJNIPzJiaB?=	M1;1fmROW09?	Ml\RTWM2OD1zMDFOwG0>	NUjSdpRCOjN6NESwN\|g>
NCI-H146	NVXPWmFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfCbIh[OTBizszN	NU\JT21mPzJiaB?=	MkO5SG1UVw>?	M{TNfmlEPTB;MUCg{txO	MVSyN\|g1PDB\|OB?=
NCI-H157	NGDpTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrHNo8yOCEQvF2=	M{P6NFczKGh?	NYHob2E6TE2VTx?=	NI[0S\|NKSzVyPUGwJO69VQ>?	M3\meFI{QDR2MEO4
NCI-H187	NYnlTXFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{D5WFExKM7:TR?=	NEfoR2o4OiCq	NE\k[ZlFVVOR	NUKwNIVVUUN3ME2xNEDPxE1?	NGrVbJgzOzh2NECzPC=>
NCI-H209	NXXRO3dCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2i2VFExKM7:TR?=	M1PtbVczKGh?	MlnMSG1UVw>?	NYrEcZJ2UUN3ME2xNEDPxE1?	NYG0TVZxOjN6NESwN\|g>
NCI-H226	NVvXWGIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYOxNEDPxE1?	MXS3NkBp	M3HKPGROW09?	M3zjZWlEPTB;MUCg{txO	M4PhSFI{QDR2MEO4
NCI-H292	M3LEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVviVW9WOTBizszN	M3;UdFczKGh?	MX;EUXNQ	MmHPTWM2OD1zMDFOwG0>	NUOzcolTOjN6NESwN\|g>
NCI-H322	Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXPNVAh\|ryP	MmHPO\|IhcA>?	MkiwSG1UVw>?	M3LveWlEPTB;MUCg{txO	NI\MSpozOzh2NECzPC=>
NCI-H358	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX2xNEDPxE1?	MWq3NkBp	MXjEUXNQ	NFnkdVhKSzVyPUGwJO69VQ>?	NEfYRXEzOzh2NECzPC=>
NCI-H520	MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHMZ5YyOCEQvF2=	MmLYO\|IhcA>?	Mn3pSG1UVw>?	M1f4UmlEPTB;MUCg{txO	MX[yN\|g1PDB\|OB?=
NCI-H526	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELTNWIyOCEQvF2=	MYm3NkBp	MWTEUXNQ	NXHhUpl2UUN3ME2xNEDPxE1?	M2\CflI{QDR2MEO4
NCI-H630	NVv2W25jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{W1OVExKM7:TR?=	NVLCdnd2PzJiaB?=	M{nZT2ROW09?	NXy3V3d6UUN3ME2xNEDPxE1?	Mn\HNlM5PDRyM{i=
NCI-H661	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnaNVAh\|ryP	NH\4SVU4OiCq	NIrqVZFFVVOR	MXnJR\|UxRTFyIN88US=>	M2K5OVI{QDR2MEO4
NCI-H716	NX76ZZJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX:xNEDPxE1?	M{jY[VczKGh?	M{T4W2ROW09?	MVnJR\|UxRTFyIN88US=>	NHjIfIQzOzh2NECzPC=>
NCI-H1563	MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVexNEDPxE1?	M17rTlczKGh?	MYnEUXNQ	NUXQdWs2UUN3ME2xNEDPxE1?	MW[yN\|g1PDB\|OB?=
NCI-H1792	M4Lzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILweVgyOCEQvF2=	MWG3NkBp	NHT2ZnBFVVOR	NYrMWHhXUUN3ME2xNEDPxE1?	MmT1NlM5PDRyM{i=
NCI-H2030	NXHXRXJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;CNHIyOCEQvF2=	NEfsc2Q4OiCq	MX7EUXNQ	M{PvW2lEPTB;MUCg{txO	M136dlI{QDR2MEO4
NCI-H2052	M4PWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoSzNVAh\|ryP	MV:3NkBp	NV7JW5VPTE2VTx?=	MlnITWM2OD1zMDFOwG0>	NHPhSXczOzh2NECzPC=>
NCI-H2122	NGPS[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXSxNEDPxE1?	NE\DR\|Y4OiCq	NFfF[HVFVVOR	NVTvUIJvUUN3ME2xNEDPxE1?	NIPnPWczOzh2NECzPC=>
NCI-H2228	NYSzVWsxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLPNVAh\|ryP	NGi1OVc4OiCq	NEH6e2FFVVOR	NU\kR4ZVUUN3ME2xNEDPxE1?	NYXheW1sOjN6NESwN\|g>
OE-19	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILIcZAyOCEQvF2=	NYHoTGNSPzJiaB?=	MoTySG1UVw>?	NV7hWoN3UUN3ME2xNEDPxE1?	Mlq4NlM5PDRyM{i=
OE-21	NH73do9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUGxNEDPxE1?	MlG3O\|IhcA>?	MVrEUXNQ	Mnu1TWM2OD1zMDFOwG0>	M2m3e\|I{QDR2MEO4
OE-33	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzlNVAh\|ryP	NFz6UIQ4OiCq	MXrEUXNQ	NHnnUmdKSzVyPUGwJO69VQ>?	MoLXNlM5PDRyM{i=
OVCAR-3	NVTjOo0xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;wZVExKM7:TR?=	NXTP[IxlPzJiaB?=	NWnUc49HTE2VTx?=	M2jZcmlEPTB;MUCg{txO	NI\0[pgzOzh2NECzPC=>
OVCAR-4	M33pRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV[xNEDPxE1?	NFP5bHI4OiCq	NXGwcHFDTE2VTx?=	Ml3qTWM2OD1zMDFOwG0>	Ml3YNlM5PDRyM{i=
OVCAR-5	NIixSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXexNEDPxE1?	MmHLO\|IhcA>?	NFLaNZhFVVOR	MUDJR\|UxRTFyIN88US=>	NEi4Rm0zOzh2NECzPC=>
P3HR-1	M2nUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fBVFExKM7:TR?=	NF\qb\|U4OiCq	MVLEUXNQ	MnLTTWM2OD1zMDFOwG0>	M3u5NVI{QDR2MEO4
PC-3	NEPmWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUCxNEDPxE1?	MV[3NkBp	NEXZTYpFVVOR	MkTyTWM2OD1zMDFOwG0>	M3TpZ\|I{QDR2MEO4
Raji	M3n5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmD1NVAh\|ryP	MWe3NkBp	MXLEUXNQ	M4Hk[mlEPTB;MUCg{txO	MmD3NlM5PDRyM{i=
RD	M1OzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnjNVAh\|ryP	NU\ncmtTPzJiaB?=	NUjlPJN2TE2VTx?=	M2jJdmlEPTB;MUCg{txO	MoTNNlM5PDRyM{i=
RD-ES	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4K1eFExKM7:TR?=	M3;rU\|czKGh?	Mly3SG1UVw>?	NFnOSJlKSzVyPUGwJO69VQ>?	NYLJPJlsOjN6NESwN\|g>
RL	NV7IdoxkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XCZ\|ExKM7:TR?=	MUm3NkBp	MlruSG1UVw>?	NWLES2hsUUN3ME2xNEDPxE1?	NWqxR3VJOjN6NESwN\|g>
SaOS2	M1P4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7FSZRWOTBizszN	MUO3NkBp	NH7ocJpFVVOR	NInIRlBKSzVyPUGwJO69VQ>?	NH63cFkzOzh2NECzPC=>
SCC-9	NYrvW5ZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fsd\|ExKM7:TR?=	MWS3NkBp	M2rP[mROW09?	NXnhZolkUUN3ME2xNEDPxE1?	NHHxSFUzOzh2NECzPC=>
SCC-12	M3zGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXqxNEDPxE1?	MmPOO\|IhcA>?	NGP3fIRFVVOR	MnmwTWM2OD1zMDFOwG0>	NEf5OXgzOzh2NECzPC=>
SCC-13	M4\VRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGH6PJEyOCEQvF2=	NGLYepI4OiCq	MnHCSG1UVw>?	MVHJR\|UxRTFyIN88US=>	M1nCVVI{QDR2MEO4
SCC-15	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NICxOYQyOCEQvF2=	NVG1cYxpPzJiaB?=	M2GydmROW09?	MXLJR\|UxRTFyIN88US=>	MXuyN\|g1PDB\|OB?=
SCC-25	NEnlXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nTcFExKM7:TR?=	NIHmSHY4OiCq	MXvEUXNQ	MUnJR\|UxRTFyIN88US=>	MnfhNlM5PDRyM{i=
SCLC-3	Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjHc2E2OTBizszN	M{fuU\|czKGh?	MmW3SG1UVw>?	MkHQTWM2OD1zMDFOwG0>	Mn\zNlM5PDRyM{i=
SF-268	M1LTcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHSZolLOTBizszN	MnrBO\|IhcA>?	NYTnWIlkTE2VTx?=	NE[5eJFKSzVyPUGwJO69VQ>?	MoK3NlM5PDRyM{i=
SF-295	NXrhdZQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfXc44yOCEQvF2=	MmXPO\|IhcA>?	MW\EUXNQ	NEXvZZVKSzVyPUGwJO69VQ>?	MoP0NlM5PDRyM{i=
SJRH30	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPiPXVtOTBizszN	MWi3NkBp	M4DafGROW09?	M1mwNGlEPTB;MUCg{txO	M3TkSVI{QDR2MEO4
SK-BR-3	MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVWxNEDPxE1?	M1r2W\|czKGh?	M2L6TmROW09?	M1rlTWlEPTB;MUCg{txO	M3W1O\|I{QDR2MEO4
SK-LMS-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHTNYRKOTBizszN	M1rHdVczKGh?	MUPEUXNQ	M{H3dGlEPTB;MUCg{txO	MXqyN\|g1PDB\|OB?=
SK-N-DZ	MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGj2XpMyOCEQvF2=	MVO3NkBp	M3vRSWROW09?	NWDlR2lDUUN3ME2xNEDPxE1?	Ml\oNlM5PDRyM{i=
SK-N-F1	MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7rNVAh\|ryP	M3fSe\|czKGh?	Ml7ISG1UVw>?	M{PjXGlEPTB;MUCg{txO	NXTJNlZ[OjN6NESwN\|g>
SKOV-3	MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWOxNEDPxE1?	MoLoO\|IhcA>?	NInY[pZFVVOR	M1zBV2lEPTB;MUCg{txO	MV6yN\|g1PDB\|OB?=
SK-UT-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWX5c\|kyOTBizszN	M3K5TFczKGh?	NXq4O5FVTE2VTx?=	MX\JR\|UxRTFyIN88US=>	MkTZNlM5PDRyM{i=
SN12C	NXHOdWlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX2xNEDPxE1?	M2DCNVczKGh?	MmHMSG1UVw>?	NU\Zb5IzUUN3ME2xNEDPxE1?	NWnuVnFvOjN6NESwN\|g>
SNB-19	NEfUe\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXDU3oyOCEQvF2=	NUnhU3g4PzJiaB?=	MVnEUXNQ	NUTifll7UUN3ME2xNEDPxE1?	M4TUPVI{QDR2MEO4
SNU-5	NFz6bYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUexNEDPxE1?	MnPrO\|IhcA>?	M4KwR2ROW09?	M3uwNGlEPTB;MUCg{txO	M17wWFI{QDR2MEO4
SNU-16	NWTJUFZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jFcVExKM7:TR?=	MVO3NkBp	MVfEUXNQ	MXfJR\|UxRTFyIN88US=>	Mne5NlM5PDRyM{i=
SNU-398	NV7LTYRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vXbVExKM7:TR?=	MWW3NkBp	M17oTGROW09?	NE\IPJdKSzVyPUGwJO69VQ>?	M4n5T\|I{QDR2MEO4
SNU-449	MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHNdpJyOTBizszN	M{fBblczKGh?	MmnWSG1UVw>?	MVTJR\|UxRTFyIN88US=>	MnL4NlM5PDRyM{i=
SR	NGDKemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4H4NlExKM7:TR?=	NHPnUVk4OiCq	MXjEUXNQ	NFjHcXNKSzVyPUGwJO69VQ>?	M2HadVI{QDR2MEO4
ST486	NXjvToZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHToOJYyOCEQvF2=	MofiO\|IhcA>?	NVXrPZJGTE2VTx?=	MnPrTWM2OD1zMDFOwG0>	NXPTeGNxOjN6NESwN\|g>
SW579	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml34NVAh\|ryP	M2rzbFczKGh?	NHKzSoRFVVOR	NEjnPZJKSzVyPUGwJO69VQ>?	MV2yN\|g1PDB\|OB?=
SW684	NGDiNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnm4NVAh\|ryP	M2\IflczKGh?	NVPh[Yc6TE2VTx?=	M1TpWGlEPTB;MUCg{txO	Mk\LNlM5PDRyM{i=
SW-780	M1\TfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHUZlEyOTBizszN	NHzkbGE4OiCq	Mn;5SG1UVw>?	MV7JR\|UxRTFyIN88US=>	NID5fZgzOzh2NECzPC=>
SW900	NVS4eFc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPYbIZbOTBizszN	M3nqR\|czKGh?	NWj6U3Z7TE2VTx?=	M{[1TGlEPTB;MUCg{txO	M4X0ZVI{QDR2MEO4
SW1088	MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLHT\|UyOCEQvF2=	NXizZoY2PzJiaB?=	MYXEUXNQ	NH;nc3dKSzVyPUGwJO69VQ>?	NHLkfWgzOzh2NECzPC=>
SW1463	NX;GXnM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXixNEDPxE1?	M2L6NlczKGh?	MojrSG1UVw>?	NX7JeZlGUUN3ME2xNEDPxE1?	NYH6b3kyOjN6NESwN\|g>
SW1990	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfjNVAh\|ryP	NFvodnU4OiCq	M37qbWROW09?	MlHXTWM2OD1zMDFOwG0>	MkDKNlM5PDRyM{i=
T47D	M1;kfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnhNVAh\|ryP	M13Zb\|czKGh?	NHfGVolFVVOR	MmHkTWM2OD1zMDFOwG0>	MYmyN\|g1PDB\|OB?=
TE381.T	NYixO4VoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NESwZ5EyOCEQvF2=	M2Ppe\|czKGh?	NXL3VVc3TE2VTx?=	NFPmTm5KSzVyPUGwJO69VQ>?	NHzoV\|czOzh2NECzPC=>
TK-10	MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjUNVAh\|ryP	MVe3NkBp	MlfxSG1UVw>?	M2C5eGlEPTB;MUCg{txO	MYeyN\|g1PDB\|OB?=
U2OS	M3rFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIOy[VMyOCEQvF2=	MXm3NkBp	MoL3SG1UVw>?	MV3JR\|UxRTFyIN88US=>	M3XVOVI{QDR2MEO4
U251	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDTVG12OTBizszN	NEW0TI84OiCq	MYHEUXNQ	M{\Gc2lEPTB;MUCg{txO	NU\HbYEyOjN6NESwN\|g>
UACC-812	M3nXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzxZ2dPOTBizszN	M2e4NVczKGh?	NV7sblBqTE2VTx?=	NWHGN2tCUUN3ME2xNEDPxE1?	M2DTbFI{QDR2MEO4
YAPC	NEj6WllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPINY0yOCEQvF2=	M17ZPVczKGh?	M1PpV2ROW09?	NHzaZXJKSzVyPUGwJO69VQ>?	NXPwcIJ5OjN6NESwN\|g>
ZR-75-1	MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\kUlExKM7:TR?=	NUXxR4RuPzJiaB?=	M4rnZWROW09?	NIrpTXZKSzVyPUGwJO69VQ>?	NFrpco4zOzh2NECzPC=>
A375	M{XtXGZ2dmO2aX;uJIF{e2G7	NY\5dGs2OS5{IN88US=>	M{\MNFQhcA>?	MlfzSG1UVw>?	NVfF[ml5UW6qaXLpeIlwdiCxZjDwbI9{eGixconsZZRqd25ib3[gUWVMNCCHUlusJIFv\CCVNmC=	M2HKO\|IzOzh7NEex
YUSIT1	M{DzUWZ2dmO2aX;uJIF{e2G7			MlztSG1UVw>?	NFu4bXpz\WS3Y3XkJJNmdnOrdHn2bZR6KHerdHigTWM2OCB-IECuOUDPxE1?	NHLmOGwzOjN6OUS3NS=>
MeWo	NU\kOpU1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NVPnS2s3TE2VTx?=	MVjJR\|UxKD1iOUi3JI5O	NXv4V2RvOjZyMUi1NlQ>
WiDr	NWK3R4oxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MWHEUXNQ	M{LYfmlEPTBiPTC3OkBvVQ>?	MWmyOlAyQDV{NB?=
Colo-205	NV;STJlDTnWwY4Tpc44h[XO\|YYm=	Ml7uNUDPxE1?	MXe0JIQ>	NEHoVZlFVVOR	M33RWWlv\HWlZXSgZUBpcWeqbImgZ49ueGG{YXLs[UBkd22yYXP0bY9vKHCqZX7veJlx\Q>?	NX7hWGhyOjV\|OEGxOVI>
RBW-1	MYnGeY5kfGmxbjDhd5NigQ>?	MonINUDPxE1?		Mme1SG1UVw>?	NVnVbnhUVm9icnXkeYN1cW:wIH;mJG1mcyBzL{KgdIhwe3Cqb4L5cIF1cW:w	NGL0RoszPDh6NU[5NC=>
RBO-1	M3WyNmZ2dmO2aX;uJIF{e2G7	NWLjNIVMOSEQvF2=		MXXEUXNQ	M3fEfWlvcGmkaYTpc44hd2ZiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	MkHNNlQ5QDV4OUC=
RBO-2	NULlfYF2TnWwY4Tpc44h[XO\|YYm=	MUWxJO69VQ>?		NV;zfWdYTE2VTx?=	MWDJcohq[mm2aX;uJI9nKCCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=>	MlvZNlQ5QDV4OUC=
RBOW	NFXyT4dHfW6ldHnvckBie3OjeR?=	NFXLbFgyKM7:TR?=		MXfEUXNQ	M4PiSmlvcGmkaYTpc44hd2ZiIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v	MUiyOFg5PTZ7MB?=
M257	NGHOZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPLNVAxKG6P	MYW3NkBp		NHfKbZhFd2W\|IH7veEBqdmirYnn0JJBzd2yrZnXyZZRqd25ib3[gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[=	NHPENmkzOzNzN{S0Oi=>
LCP	NGC4OFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jwflExOCCwTR?=	MWG3NkBp		NH[wN2NKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiTFPQJINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEDSJI12fGGwdHH0bY9v	M1;kWlI{OzF5NES2
WM266	Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYqxNFAhdk1?	NVfPUnlZPzJiaB?=		MmTsTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKFePMk[2JINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEHEJI12fGGwdHH0bY9v	NITuT3YzOzNzN{S0Oi=>
M257	Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVWxNFAhdk1?	M3TiUVczKGh?		NIi4NlJFd2W\|IH7veEBqdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[=	NGXjWnYzOzNzN{S0Oi=>
LCP	NWjKW4ExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M323e\|ExOCCwTR?=	M{PxdVczKGh?		M1PETmlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDMR3Ah[2WubDDoZZJjd3W{aX7nJGJTSUZiVk[wNHIhdXW2YX70ZZRqd25?	NIfOSY0zOzNzN{S0Oi=>
WM266	M1fsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4qzfFExOCCwTR?=	Ml\XO\|IhcA>?		NIW1PWlKdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gW20zPjZiY3XscEBp[XKkb4XybY5oKEKUQV[gWlYxOERibYX0ZY51[XSrb36=	M3XzSFI{OzF5NES2

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pMEK / pERK / ERK; PubMed: 31158244 PLoS One Cell lines as shown were treated with dabrafenib, over a dose range, for 1 hour. UT = untransfected. Expression and/or phosphorylation of the indicated proteins were assessed by immunoblot. p-S6 / p-AKT308 / p-AKT473; PubMed: 24735930 Mol Cancer Western blot analysis of phosphorylated proteins in MAPK and the PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib. β-catenin; PubMed: 29167314 Mol Cancer Ther HT-29 cells were treated with BRAF inhibitors Dabrafenib (2 μM), GDC-0879 (4 μM) or Vemurafenib (2 μM) for indicated times. The whole cell lysates were used for western blot with indicated antibodies.	31158244 24735930 29167314
Growth inhibition assay	IC50; PubMed: 24735930 Mol Cancer A panel of 23 BRAF(V600) mutant human melanoma cell lines was treated with serial dilutions (1-10,000 nM) of dabrafenib (A) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM.	24735930

In vivo

Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. ^[1]

Protocol

References

Solubility (25°C)

In vitro	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+45% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dabrafenib (GSK2118436) SDF

Molecular Weight	519.56
Formula	C₂₃H₂₀F₃N₅O₂S₂
CAS No.	1195765-45-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04059224	Recruiting	Drug: Trametinib\|Drug: Dabrafenib	Stage IV Melanoma\|Stage III Melanoma	Universitair Ziekenhuis Brussel	January 28 2019	Phase 2
NCT03668431	Recruiting	Drug: Dabrafenib\|Drug: Trametinib\|Drug: PDR001	Metastatic Colorectal Cancer	Massachusetts General Hospital\|Novartis\|Stand Up To Cancer	October 15 2018	Phase 2
NCT03553329	Completed	Drug: dabrafenib	Unresecable Stage IIIc or IV Melanoma	Poitiers University Hospital	June 2 2018	--
NCT03593993	Recruiting	Procedure: Surgical Cohort	Glioma\|BRAF V600E\|Pleomorphic Xantho-Astrocytoma\|Glioblastoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Musella Foundation	May 19 2018	--
NCT03340506	Recruiting	Drug: dabrafenib\|Drug: trametinib	Melanoma\|Non Small Cell Lung Cancer\|Solid Tumor\|Rare Cancers\|High Grade Glioma	Novartis Pharmaceuticals\|Novartis	December 28 2017	Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Pan Raf Inhibitor

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA-approved Raf Inhibitor

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
Newest Raf Inhibitor

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Related Raf Products

LY3009120 ^New

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.
Ravoxertinib (GDC-0994) ^New

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523, VRT752271) ^New

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032, RG7204)

Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Sorafenib

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Sorafenib Tosylate

Sorafenib Tosylate is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
PLX-4720

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
TAK-632

TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
GDC-0879

GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.
GW5074

GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted.

Choose Your Country or Region

By Signaling Pathways

By product type

Dabrafenib (GSK2118436)

Cited by 104 Publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dabrafenib (GSK2118436) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products

Choose Your Country or Region

By Signaling Pathways

By product type

Dabrafenib (GSK2118436)

Cited by 104 Publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dabrafenib (GSK2118436) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)